ABSTRACT

This textbook examines the most important aspects of multiple sclerosis that impact on clinical trial design, on the development of new disease therapies and on patient care. The international team of contributors discuss the clinical course of multiple sclerosis, its clinical heterogeneity, the presence of subclinical disease activity which occurs

part I|2 pages

Introduction

part II|2 pages

Clinical trial methodology

part III|2 pages

Clinical trials of disease modifying therapy

chapter 20|34 pages

Interferons

chapter 21|22 pages

Glatiramer acetate

chapter 22|10 pages

Cladribine

chapter 24|12 pages

Therapeutic plasma exchange

chapter 26|22 pages

Methylprednisolone

chapter 29|10 pages

Combination therapies

part V|2 pages

Symptomatic drug therapy in clinical practice